Selection of first-line systemic therapies for advanced hepatocellular carcinoma: A network meta-analysis of randomized controlled trials

doi:10.3748/wjg.v27.i19.2415

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 27, Issue 19

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Supplementary Materials of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (9274)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-3) series, Tables (1-2) series.

Item

Count

PDF

739

WORD

217

HTML

6414

Figures (1-3)

275

Tables (1-2)

234

Sum=7879

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

430

Download

965

Sum=1395

May 21, 2021 (publication date) through Sep 20, 2024

Times Cited of This Article

Times Cited (15)

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Meta-Analysis

World J Gastroenterol. May 21, 2021; 27(19): 2415-2433
Published online May 21, 2021. doi: 10.3748/wjg.v27.i19.2415

Full Size Figure Download Figure

Figure 3 Survival outcomes in patients with advanced hepatocellular carcinoma following first-line systemic therapy. A, C, and E: Network diagrams; B: Interventions ranked by P value with hazard ratios for progression-free survival, D: Time to progression and F: overall survival for each treatment vs lenvatinib. CI: Confidence interval; FOLFOX4: Oxaliplatin/folinic acid/5-fluorouracil; HCC: Hepatocellular carcinoma; HR: Hazard ratio; OS: Overall survival; PIAF: Cisplatin/interferon α-2b/doxorubicin/5-fluorouracil; TTP: Time to progression.

Citation: Han Y, Zhi WH, Xu F, Zhang CB, Huang XQ, Luo JF. Selection of first-line systemic therapies for advanced hepatocellular carcinoma: A network meta-analysis of randomized controlled trials. World J Gastroenterol 2021; 27(19): 2415-2433
URL: https://www.wjgnet.com/1007-9327/full/v27/i19/2415.htm
DOI: https://dx.doi.org/10.3748/wjg.v27.i19.2415